Articles From: Mylan Launches First Generic Version of Orapred ODT® to Myriad Genetics to Announce 2Q15 Financial Results on February 3, 2015


- Company awarded 180 days of marketing exclusivity - PITTSBURGH , Dec.
Sign-up for Mylan Launches First Generic Version of Orapred ODT® investment picks
PITTSBURGH , Dec.
Sign-up for Mylan Launches First Generic Version of Vivelle-DOT® investment picks
PITTSBURGH , Jan.
Sign-up for Mylan Launches Generic Diovan® Tablets investment picks
PITTSBURGH , Jan.
Sign-up for Mylan Launches Generic Epivir-HBV® Tablets investment picks
PITTSBURGH , Nov.
Sign-up for Mylan Launches Generic Loestrin 24 Fe® investment picks
PITTSBURGH , Dec.
Sign-up for Mylan Launches Generic Robaxin® Injection investment picks
PITTSBURGH , Oct.
Sign-up for Mylan Launches Generic Viramune XR® investment picks
PITTSBURGH , Dec.
Sign-up for Mylan Launches One of First Available Generic Versions of Celebrex® Capsules investment picks
PITTSBURGH and HYDERABAD, India , Dec.
Sign-up for Mylan Signs Agreement with Gilead to Enhance Access to Tenofovir Alafenamide (TAF)-based HIV Treatments in Developing Countries investment picks
EpiPen® Auto-Injector Locations Designated on Updated Guide Maps and Signage New Multi-year Alliance to Increase Anaphylaxis Awareness through Multiple Educational Initiatives PITTSBURGH , Nov.
Sign-up for Mylan Signs Strategic Alliance Agreement with Walt Disney Parks and Resorts to Enhance Access to EpiPen® (epinephrine) Auto-Injectors investment picks
2014 Adjusted Diluted EPS Guidance Range Increases to $3.54 to $3.60 PITTSBURGH , Oct.
Sign-up for Mylan Third Quarter 2014 Adjusted Diluted EPS Increases 41% to $1.16 investment picks
By Angela Chen Gilead Sciences Inc. will allow a subsidiary of the pharmaceutical company Mylan Inc. to have nonexclusive rights to manufacture and distribute its HIV treatment drug in 112 countries.
Sign-up for Mylan to manufacture, distribute Gilead Sciences HIV drug investment picks
PITTSBURGH , Dec.
Sign-up for Mylan to Present at the J.P. Morgan 33rd Annual Healthcare Conference investment picks
http://media.marketwire.com/attachments/201411/81914_myos.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1159794&ProfileId=051205&sourceType=1 CEDAR KNOLLS, NJ --
Sign-up for MYOS Corporation Announces $1.81 Million Registered Direct Offering investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1156044&ProfileId=051205&sourceType=1 CEDAR KNOLLS, NJ --
Sign-up for MYOS Corporation Announces Positive Safety Data Demonstrating Fortetropin's(TM) Lack of Adverse Effect on Serum Lipids and Cholesterol Levels investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1155092&ProfileId=051205&sourceType=1 CEDAR KNOLLS, NJ --
Sign-up for MYOS Corporation Announces Statistically Significant Top-Line Clinical Data Demonstrating Fortetropin's(TM) Anti-Inflammatory BioTherapeutic Properties investment picks
http://media.marketwire.com/attachments/201210/52097_MYOS.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1159041&ProfileId=051205&sourceType=1 CEDAR KNOLLS, NJ --
Sign-up for MYOS Corporation Reports 2014 Third Quarter Results and Provides Business Update investment picks
Loyalty marketing service MyPoints.com, Inc., a subsidiary of United Online, Inc. (NASDAQ: UNTD), announced today the launch of its updated website, iOS mobile app and browser extension designed to allow members to earn Points when they shop at over 1,500 MyPoints affiliated retailers, while dramatically improving their online shopping experience.
Sign-up for MyPoints Launches Redesigned Website, Mobile App and Browser Extension Powering Enhanced Rewards-Based Online Shopping Experience investment picks
ROLLING MEADOWS, Ill., Nov.
Sign-up for MYR Group Inc. Announces Third-Quarter and First Nine-Months 2014 Results investment picks
SALT LAKE CITY, Nov.
Sign-up for Myriad and AbbVie Sign Expanded Agreement for Tumor BRACAnalysis CDx(TM) investment picks
SALT LAKE CITY, Oct.
Sign-up for Myriad Announces Inclusion of Prolaris(R) Test in NCCN Guidelines investment picks
SALT LAKE CITY, Oct.
Sign-up for Myriad Appoints R. Bryan Riggsbee as Chief Financial Officer investment picks
SALT LAKE CITY and ZURICH, Oct.
Sign-up for Myriad Establishes Tumor BRACAnalysis CDx(TM) Laboratory in Europe investment picks
SALT LAKE CITY, Dec.
Sign-up for Myriad Genetics Names Bernard Tobin as President of Crescendo Bioscience investment picks
Revenue of $168.8 million; diluted EPS of $0.21; adjusted EPS of $0.25 myRisk Hereditary Cancer revenue of $53.1 million, up 95 percent sequentially Draft Medicare decision covering Prolaris for low-risk prostate cancer patients CHMP recommends approval of olaparib in ovarian cancer patients with BRCA mutations Company reiterates fiscal year 2015 financial guidance; provides FY2Q15 financial guidance SALT LAKE CITY, Nov.
Sign-up for Myriad Genetics Reports Fiscal First Quarter 2015 Financial Results investment picks
SALT LAKE CITY, Oct.
Sign-up for Myriad Genetics to Announce 1Q15 Financial Results on November 4, 2014 investment picks
SALT LAKE CITY, Jan.
Sign-up for Myriad Genetics to Announce 2Q15 Financial Results on February 3, 2015 investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Mylan Launches First Generic Version of Orapred ODT® to Myriad Genetics to Announce 2Q15 Financial Results on February 3, 2015
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent